Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P La Rosée

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Der Internist|February 2, 2013
[Tailored management of chronic myeloid leukemia]A Hochhaus, P La Rosée
Leukemia|June 25, 2004
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceA Hochhaus, P La Rosée
Zeitschrift Fur Rheumatologie|January 14, 2018
[Rheumatoid symptoms in patients with hematologic neoplasms]S Kleinert, P La Rosée, K Krüger
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|February 13, 2021
[Hemophagocytic lymphohistiocytosis in critically ill patients]D A Eichenauer, G Lachmann, P La Rosée
Leukemia|July 3, 2002
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspectiveP La Rosée, M E O'Dwyer, B J Druker
Der Internist|April 11, 2015
[Chronic myelogenous leukemia]A Hochhaus, P La Rosée, E Eigendorff, et al.
Der Anaesthesist|September 11, 2016
[Hemophagocytic lymphohistiocytosis : A diagnostic challenge on the ICU]G Lachmann, P La Rosée, T Schenk, et al.
Leukemia|October 3, 2009
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient historyE Jabbour, A Hochhaus, J Cortes, et al.
Journal of Cancer Research and Clinical Oncology|December 15, 2015
A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphomaF Hunstig, S Schulz, I Nieten, et al.
Leukemia|February 1, 2012
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptorsT Klag, N Härtel, P Erben, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Der Internist|February 2, 2013
[Tailored management of chronic myeloid leukemia]A Hochhaus, P La Rosée
Leukemia|June 25, 2004
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceA Hochhaus, P La Rosée
Zeitschrift Fur Rheumatologie|January 14, 2018
[Rheumatoid symptoms in patients with hematologic neoplasms]S Kleinert, P La Rosée, K Krüger
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|February 13, 2021
[Hemophagocytic lymphohistiocytosis in critically ill patients]D A Eichenauer, G Lachmann, P La Rosée
Leukemia|July 3, 2002
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspectiveP La Rosée, M E O'Dwyer, B J Druker
Der Internist|April 11, 2015
[Chronic myelogenous leukemia]A Hochhaus, P La Rosée, E Eigendorff, et al.
Der Anaesthesist|September 11, 2016
[Hemophagocytic lymphohistiocytosis : A diagnostic challenge on the ICU]G Lachmann, P La Rosée, T Schenk, et al.
Leukemia|October 3, 2009
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient historyE Jabbour, A Hochhaus, J Cortes, et al.
Journal of Cancer Research and Clinical Oncology|December 15, 2015
A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphomaF Hunstig, S Schulz, I Nieten, et al.
Leukemia|February 1, 2012
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptorsT Klag, N Härtel, P Erben, et al.
Pageof 3